Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.
Cancer Genomics and Genetics Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 8006, Australia; and the Kinghorn Cancer Centre, Garvan Institute for Medical Research, Darlinghurst, Sydney, 2010 New South Wales, Australia.
David D
DD
Bowtell
Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M6BQ, UK.
Steffen
S
Böhm
Nuffield Department of Obstetrics and Gynaecology and the Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK.
Ahmed A
AA
Ahmed
Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, USA.
Paul-Joseph
PJ
Aspuria
MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030-4009, USA.
Robert C
RC
Bast
University of Oxford, Headington, Oxford, OX3 7LF, UK.
Valerie
V
Beral
Stanford University, Stanford, California 94305, USA.
Jonathan S
JS
Berek
Massachusetts General Hospital, Boston, Massachusetts 02114 USA.
Michael J
MJ
Birrer
Ovarian Cancer Action Research Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
Sarah
S
Blagden
Arizona Oncology, Tucson, Arizona 85711, USA.
Michael A
MA
Bookman
Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK.
James D
JD
Brenton
The Sidney Kimmel Cancer Center at John Hopkins University, Baltimore, Maryland 21287, USA.
Katherine B
KB
Chiappinelli
Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK.
Filipe Correia
FC
Martins
University Hospital of Lausanne, Lausanne, Switzerland.
George
G
Coukos
University of Pennsylvania, Penn Ovarian Cancer Research Center, Philadelphia, Pennsylvania 19104, USA.
Ronny
R
Drapkin
University of Manchester, Manchester M13 9WL, UK.
Richard
R
Edmondson
Ovarian Cancer Action Research Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
Christina
C
Fotopoulou
Ovarian Cancer Action Research Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
Hani
H
Gabra
Institut National de la Santé et de la Recherche Médicale, UMRS1138, Laboratory of Integrative Cancer Immunology, Cordeliers Research Center, Université Paris Descartes, Sorbonne Paris Cité, Sorbonne Universités, UPMC Univ Paris 06, 75006 Paris, France.
Jérôme
J
Galon
Cancer Research Centre, University of Edinburgh, Edinburgh EH4 2XR, UK.
Charlie
C
Gourley
Walter and Eliza Hall Institute, Parkville, Victoria 3052, Australia.
Valerie
V
Heong
University of British Columbia, Departments of Pathology and Laboratory Medicine and Obstetrics and Gynecology, Faculty of Medicine, Vancouver, British Columbia V6T 2B5, Canada.
David G
DG
Huntsman
Harvard Medical School, Boston, Massachusetts 02115, USA.
Marcin
M
Iwanicki
Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, USA.
Beth Y
BY
Karlan
Ovarian Cancer Action, London NW1 OJH, UK.
Allyson
A
Kaye
University of Chicago, Chicago, Illinois 60637, USA.
Ernst
E
Lengyel
Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Douglas A
DA
Levine
MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030-4009, USA.
Karen H
KH
Lu
University of Glasgow, Glasgow G61 1QH, UK.
Iain A
IA
McNeish
Women's Cancer, Institute for Women's Health, University College London, London WC1E 6BT, UK.
Usha
U
Menon
Women's College Research Institute, Toronto, Ontario M5G 1N8, Canada.
Steven A
SA
Narod
British Columbia Cancer Agency, Victoria, British Columbia V8R 6V5, Canada.
Brad H
BH
Nelson
Indiana University School of Medicine &Simon Cancer Center, Bloomington, IN 47405-4401, USA.
Kenneth P
KP
Nephew
University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK.
Paul
P
Pharoah
University of Pennsylvania, Philadelphia, PA 19104-5156, USA.
Daniel J
DJ
Powell
Translational Genomics Research Institute (Tgen), Phoenix, Arizona 85004, USA.
Pilar
P
Ramos
University of Chicago, Chicago, Illinois 60637, USA.
Iris L
IL
Romero
Walter and Eliza Hall Institute, Parkville, Victoria 3052, Australia.
Clare L
CL
Scott
MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030-4009, USA.
Anil K
AK
Sood
Ovarian Cancer Action Research Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
Euan A
EA
Stronach
Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M6BQ, UK.
Frances R
FR
Balkwill
D018284:Cystadenocarcinoma, Serous / Q000401:mortality* / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D060787:Neoplasm Grading; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000473:pathology / Q000517:prevention & control*; D011379:Prognosis; D015996:Survival Rate